Drug firm raises €33m to fund work on kidney transplant treatment
The money will go towards funding clinical studies into the former Trinity College campus company’s lead product — code-named ‘OPN-305’ — which is aimed at treating a range of inflammatory diseases and conditions; from rheumatoid arthritis, diabetes and lupus to various forms of cancer.
This will be the first detailed clinical study into OPN-305, but the drug recently completed a successful Phase-1 clinical trial, in healthy human volunteers and has also demonstrated activity in pre-clinical animal models and ex-vivo studies.
